Investigational drug · Phase 2
Combination of Navepegritide
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Achondroplasia.
Phase 2Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Combination of Navepegritide"
First trial start
2024
Jul 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Combination of Navepegritide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Achondroplasia
Approved drugs for the same conditions: Achondroplasia · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Combination of Navepegritide" as an intervention, largest first.
- A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With AchondroplasiaActive, not recruiting
Ascendis Pharma Growth Disorders A/SIndustry
NCT06433557 · 22 participants · Start Jul 26, 2024 · Primary completion Nov 14, 2025
Drug: Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections · For: Achondroplasia
Sites: Copenhagen, Denmark; Dublin, Ireland; London, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Achondroplasia
- Modified recombinant human C-type natriuretic peptideBMN 111Phase 32 trials
BioMarin · Achondroplasia
- BMN 333Phase 31 trial
BioMarin · Achondroplasia
- KK8398Phase 31 trial
Kyowa Kirin Co., Ltd. · Achondroplasia
- DabogratinibTYRA-300Phase 24 trials
Tyra Biosciences, Inc · FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia
- ABSK061Phase 22 trials
Abbisko Therapeutics Co, Ltd · HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.